Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer

NCT04058964 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Study withdrawn by supporter

Conditions

Metastatic Pancreatic Adenocarcinoma
Stage IV Pancreatic Cancer AJCC v8

Interventions

BIOLOGICAL: Pegylated Recombinant Human Hyaluronidase PH20
BIOLOGICAL: Pembrolizumab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]